Perspective on the use of perampanel and intravenous carbamazepine for generalized seizures

Valentina Franco, Alfonso Iudice, Elisabetta Grillo, Rita Citraro, Giovambattista De Sarro, Emilio Russo

Research output: Contribution to journalArticle

Abstract

Introduction: Several antiepileptic drugs are available for the treatment of epileptic patients. However, the treatment of some seizure types and novel drug formulations deserve further advances in epilepsy research. Areas covered: The authors analyze the published evidence on the efficacy of perampanel against secondarily generalized seizures (SGS) and report the currently available development of intravenous (IV) formulations of carbamazepine (CBZ), commenting on their potential in the clinical setting. Expert opinion: Perampanel is the first noncompetitive AMPA receptor antagonist to be approved as adjunctive treatment in patients with partial-onset (focal) seizures (POS) with or without secondary generalization. Apart from its efficacy and safety on POS, a consistent body of evidence supports its efficacy in SGS at a minimum dose of 8 mg/day; however, such dose appears close to the best-tolerated dose. CBZ is a poorly water-soluble compound; many efforts to develop a parenteral formulation have not been successful so far. Novel IV CBZ formulations seem to exhibit favorable pharmacokinetics along with good tolerability in animal models and in patients taking oral CBZ. Further studies are needed to assess whether larger doses will be as well tolerated, allowing IV CBZ to be used as bridge therapy when the oral route is not feasible or in patients naïve to CBZ.

Original languageEnglish
Pages (from-to)637-644
Number of pages8
JournalExpert Opinion on Pharmacotherapy
Volume15
Issue number5
DOIs
Publication statusPublished - 2014

Fingerprint

Carbamazepine
Seizures
Drug Compounding
AMPA Receptors
Expert Testimony
Therapeutics
Anticonvulsants
perampanel
Epilepsy
Animal Models
Pharmacokinetics
Safety
Water
Research

Keywords

  • Epilepsy
  • Intravenous carbamazepine
  • Perampanel
  • Secondarily generalized seizures

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Perspective on the use of perampanel and intravenous carbamazepine for generalized seizures. / Franco, Valentina; Iudice, Alfonso; Grillo, Elisabetta; Citraro, Rita; De Sarro, Giovambattista; Russo, Emilio.

In: Expert Opinion on Pharmacotherapy, Vol. 15, No. 5, 2014, p. 637-644.

Research output: Contribution to journalArticle

Franco, Valentina ; Iudice, Alfonso ; Grillo, Elisabetta ; Citraro, Rita ; De Sarro, Giovambattista ; Russo, Emilio. / Perspective on the use of perampanel and intravenous carbamazepine for generalized seizures. In: Expert Opinion on Pharmacotherapy. 2014 ; Vol. 15, No. 5. pp. 637-644.
@article{ddd6480966744ff3a9396124288ddf02,
title = "Perspective on the use of perampanel and intravenous carbamazepine for generalized seizures",
abstract = "Introduction: Several antiepileptic drugs are available for the treatment of epileptic patients. However, the treatment of some seizure types and novel drug formulations deserve further advances in epilepsy research. Areas covered: The authors analyze the published evidence on the efficacy of perampanel against secondarily generalized seizures (SGS) and report the currently available development of intravenous (IV) formulations of carbamazepine (CBZ), commenting on their potential in the clinical setting. Expert opinion: Perampanel is the first noncompetitive AMPA receptor antagonist to be approved as adjunctive treatment in patients with partial-onset (focal) seizures (POS) with or without secondary generalization. Apart from its efficacy and safety on POS, a consistent body of evidence supports its efficacy in SGS at a minimum dose of 8 mg/day; however, such dose appears close to the best-tolerated dose. CBZ is a poorly water-soluble compound; many efforts to develop a parenteral formulation have not been successful so far. Novel IV CBZ formulations seem to exhibit favorable pharmacokinetics along with good tolerability in animal models and in patients taking oral CBZ. Further studies are needed to assess whether larger doses will be as well tolerated, allowing IV CBZ to be used as bridge therapy when the oral route is not feasible or in patients na{\"i}ve to CBZ.",
keywords = "Epilepsy, Intravenous carbamazepine, Perampanel, Secondarily generalized seizures",
author = "Valentina Franco and Alfonso Iudice and Elisabetta Grillo and Rita Citraro and {De Sarro}, Giovambattista and Emilio Russo",
year = "2014",
doi = "10.1517/14656566.2014.879572",
language = "English",
volume = "15",
pages = "637--644",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "5",

}

TY - JOUR

T1 - Perspective on the use of perampanel and intravenous carbamazepine for generalized seizures

AU - Franco, Valentina

AU - Iudice, Alfonso

AU - Grillo, Elisabetta

AU - Citraro, Rita

AU - De Sarro, Giovambattista

AU - Russo, Emilio

PY - 2014

Y1 - 2014

N2 - Introduction: Several antiepileptic drugs are available for the treatment of epileptic patients. However, the treatment of some seizure types and novel drug formulations deserve further advances in epilepsy research. Areas covered: The authors analyze the published evidence on the efficacy of perampanel against secondarily generalized seizures (SGS) and report the currently available development of intravenous (IV) formulations of carbamazepine (CBZ), commenting on their potential in the clinical setting. Expert opinion: Perampanel is the first noncompetitive AMPA receptor antagonist to be approved as adjunctive treatment in patients with partial-onset (focal) seizures (POS) with or without secondary generalization. Apart from its efficacy and safety on POS, a consistent body of evidence supports its efficacy in SGS at a minimum dose of 8 mg/day; however, such dose appears close to the best-tolerated dose. CBZ is a poorly water-soluble compound; many efforts to develop a parenteral formulation have not been successful so far. Novel IV CBZ formulations seem to exhibit favorable pharmacokinetics along with good tolerability in animal models and in patients taking oral CBZ. Further studies are needed to assess whether larger doses will be as well tolerated, allowing IV CBZ to be used as bridge therapy when the oral route is not feasible or in patients naïve to CBZ.

AB - Introduction: Several antiepileptic drugs are available for the treatment of epileptic patients. However, the treatment of some seizure types and novel drug formulations deserve further advances in epilepsy research. Areas covered: The authors analyze the published evidence on the efficacy of perampanel against secondarily generalized seizures (SGS) and report the currently available development of intravenous (IV) formulations of carbamazepine (CBZ), commenting on their potential in the clinical setting. Expert opinion: Perampanel is the first noncompetitive AMPA receptor antagonist to be approved as adjunctive treatment in patients with partial-onset (focal) seizures (POS) with or without secondary generalization. Apart from its efficacy and safety on POS, a consistent body of evidence supports its efficacy in SGS at a minimum dose of 8 mg/day; however, such dose appears close to the best-tolerated dose. CBZ is a poorly water-soluble compound; many efforts to develop a parenteral formulation have not been successful so far. Novel IV CBZ formulations seem to exhibit favorable pharmacokinetics along with good tolerability in animal models and in patients taking oral CBZ. Further studies are needed to assess whether larger doses will be as well tolerated, allowing IV CBZ to be used as bridge therapy when the oral route is not feasible or in patients naïve to CBZ.

KW - Epilepsy

KW - Intravenous carbamazepine

KW - Perampanel

KW - Secondarily generalized seizures

UR - http://www.scopus.com/inward/record.url?scp=84896266745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896266745&partnerID=8YFLogxK

U2 - 10.1517/14656566.2014.879572

DO - 10.1517/14656566.2014.879572

M3 - Article

C2 - 24437529

AN - SCOPUS:84896266745

VL - 15

SP - 637

EP - 644

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 5

ER -